243 related articles for article (PubMed ID: 36130021)
1. Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers.
Lin C; Liu P; Shi C; Qiu L; Shang D; Lu Z; Tu Z; Liu H
Fundam Clin Pharmacol; 2023 Apr; 37(2):194-214. PubMed ID: 36130021
[TBL] [Abstract][Full Text] [Related]
2. RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.
Liu P; Lin C; Liu L; Lu Z; Tu Z; Liu H
J Biol Chem; 2022 Sep; 298(9):102354. PubMed ID: 35952757
[TBL] [Abstract][Full Text] [Related]
3. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
[TBL] [Abstract][Full Text] [Related]
4. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
5. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
7. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
[TBL] [Abstract][Full Text] [Related]
8. Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Stewart MD; Merino Vega D; Arend RC; Baden JF; Barbash O; Beaubier N; Collins G; French T; Ghahramani N; Hinson P; Jelinic P; Marton MJ; McGregor K; Parsons J; Ramamurthy L; Sausen M; Sokol ES; Stenzinger A; Stires H; Timms KM; Turco D; Wang I; Williams JA; Wong-Ho E; Allen J
Oncologist; 2022 Mar; 27(3):167-174. PubMed ID: 35274707
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination proficiency in ovarian and breast cancer patients.
Creeden JF; Nanavaty NS; Einloth KR; Gillman CE; Stanbery L; Hamouda DM; Dworkin L; Nemunaitis J
BMC Cancer; 2021 Oct; 21(1):1154. PubMed ID: 34711195
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
Wu Y; Xu S; Cheng S; Yang J; Wang Y
J Ovarian Res; 2023 Jan; 16(1):6. PubMed ID: 36611214
[TBL] [Abstract][Full Text] [Related]
12. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer.
Konstantinopoulos PA; Matulonis UA
Hematol Oncol Clin North Am; 2018 Dec; 32(6):997-1010. PubMed ID: 30390770
[TBL] [Abstract][Full Text] [Related]
14. Prediction of homologous recombination deficiency from cancer gene expression data.
Kang J; Lee J; Lee A; Lee YS
J Int Med Res; 2022 Nov; 50(11):3000605221133655. PubMed ID: 36380518
[TBL] [Abstract][Full Text] [Related]
15. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
Sun C; Yin J; Fang Y; Chen J; Jeong KJ; Chen X; Vellano CP; Ju Z; Zhao W; Zhang D; Lu Y; Meric-Bernstam F; Yap TA; Hattersley M; O'Connor MJ; Chen H; Fawell S; Lin SY; Peng G; Mills GB
Cancer Cell; 2018 Mar; 33(3):401-416.e8. PubMed ID: 29533782
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
17. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
Rabban JT; Chen LM; Devine WP
Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159
[TBL] [Abstract][Full Text] [Related]
18. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
Mehta P; Bothra SJ
Adv Genet; 2021; 108():35-80. PubMed ID: 34844716
[TBL] [Abstract][Full Text] [Related]
20. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
